BPC 157 maintains the normal functions of cells by enhancing their antioxidant capacity and protecting them from the attack of free radicals
Bottom line: There is no one-size-fits-all approach to timing L-carnitine supplementation
View on Amazon Renpho 8-Electrode Smart Body Composition Scale Tracks weight, body fat %, and lean-mass shifts the metrics that surface during GLP-1 research protocols
By Patricia Van Arnum, Editorial Director, DCAT, [email protected] Whats next Glucagon-like peptide 1 (GLP-1) agonists, used to treat Type 2 diabetes and obesity, have been a success story in the industry, with Novo Nordisk riding a blockbuster wave with Ozempic/Wegovy (semaglutide), respectively for treating Type 2 diabetes and obesity, and Eli Lilly and Company also riding the wave with Mounjaro/Zepbound (tirzepatide), a dual-activating GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 medication, respectively for treating Type 2 diabetes and obesity